Evidence map›Paper›PMID 31805851›Full record

ReviewThe journal of headache and pain2019

Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature.

Takao Takeshima, Qi Wan, Yanlei Zhang, Mika Komori, Serina Stretton, Narayan Rajan, Tamas Treuer, Kaname Ueda

Open access · goldAbstract readReview
In one paragraph

Review in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 3 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Efficacy and safety of Dingluo nasal drops for the acute treatment of migraine: a pilot randomized trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Takao TakeshimaDepartment of Neurology, Headache Center, Tominaga Hospital, Osaka, Japan.
Qi WanDepartment of Neurology, Jiangsu Province Hospital, Nanjing, China.
Yanlei ZhangEli Lilly and Company, Shanghai, China.
Mika KomoriMedicine Development Unit-Japan, Eli Lilly Japan K.K., 5-1-28, Isogamidori, chuo-ku, Kobe, 651-0086, Japan.
Serina StrettonProScribe Envision Pharma Group, Sydney, Australia.
Narayan RajanEli Lilly Australia Pty. Ltd., Sydney, Australia.
Tamas TreuerGPORWE International, Lilly Hungaria Kft, Budapest, Hungary.
Kaname UedaMedicine Development Unit-Japan, Eli Lilly Japan K.K., 5-1-28, Isogamidori, chuo-ku, Kobe, 651-0086, Japan. ueda_kaname@lilly.com.ORCID http://orcid.org/0000-0003-1967-9829
Eli Lilly (Japan) · JPJiangsu Province Hospital · CNLilly (China) · CNPharmaxis (Australia) · AUTominaga hospital · JP

Funding

Eli Lilly and Company Not Applicable
6 · The paper itself

Abstract

backgroundThe objective of this review was to determine the unmet needs for migraine in East Asian adults and children.

methodsWe searched MEDLINE and EMBASE (January 1, 1988 to January 14, 2019). Studies reporting the prevalence, humanistic and economic burden, and clinical management of migraine in China (including Hong Kong and Taiwan), Japan, and South Korea were included. Studies conducted before 1988 (before the International Headache Society [IHS] first edition of the International Classification of Headache Disorders) were not included.

resultsWe retrieved 1337 publications and 41 met the inclusion criteria (28 from China, 7 from Japan, and 6 from South Korea). The 1-year prevalence of migraine (IHS criteria) among adults ranged from 6.0% to 14.3%. Peak prevalence ranged from 11% to 20% for women and 3% to 8% for men (30- to 49-year-olds). For children, prevalence of migraine increased with age. Information on the economic burden and clinical management of migraine was limited, particularly for children. When reported, migraine was significantly associated with high levels of disability and negative effects on quality of life. Studies suggested low levels of disease awareness/diagnosis within each country. Of individuals with migraine from China, 52.9% to 68.6% had consulted a physician previously, 37.2% to 52.7% diagnosed with headache had not been diagnosed with migraine previously, and 13.5% to 18% had been diagnosed with migraine previously. Of individuals with migraine from Japan, 59.4% to 71.8% had never consulted a physician previously, 1.3% to 7.3% regularly consulted physicians for their headache, and only 11.6% of individuals with migraine were aware that they had migraine. In addition, studies suggested that over-the-counter medication use was high and prescription medication use was low in each country.

conclusionsThis review suggests that there are unmet needs for migraine in terms of sufficient and appropriate diagnosis, and better management and therapies for treatment of migraine in East Asia. The findings are limited by a lack of recent information and significant gaps in the literature. More recent, population-based studies assessing disease burden and clinical management of migraine are needed to confirm unmet needs for migraine across East Asia.

Indexed as

Cost of IllnessDisease ManagementAdultChildChinaHong KongHumansJapanMigraine DisordersPrevalenceQuality of LifeRepublic of KoreaTaiwanBurdenChinaCost of illnessEpidemiologyFar EastHong KongJapanKoreaMedical economicsMigraine disordersPrevalenceQuality of lifeTaiwan

Identifiers

PMID31805851
PMCPMC6896325
OpenAlexW2994140926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.